Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11333341 | 0.86 | CA2 (0.58) | CA2KDM4EMMP2CA1MMP1 | |
| SCHEMBL10817097 | 0.83 | CA2 (0.63) | CA2KDM4EMMP2CA1MMP1 | |
| Sulfathiourea SCHEMBL149742 | 0.82 | TSHR (0.61) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL370189 | 0.81 | CA2 (0.56) | CA2KDM4EMMP2CA1MMP1 | |
| SCHEMBL7363066 | 0.80 | ALDH1A1 (0.60) | CA2MMP2CA1MMP1MMP9 | |
| Sulfhydryl Boron Hydride SCHEMBL11663199 | 0.80 | GAA (0.63) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL1269819 | 0.79 | CA2 (0.54) | CA2KDM4EMMP2CA1MMP1 | |
| SCHEMBL10967386 | 0.79 | CA2 (0.59) | CA2KDM4EMMP2CA1MMP1 | |
| SCHEMBL6223776 | 0.79 | CA2 (0.65) | CA2KDM4EMMP2CA1MMP1 | |
| SCHEMBL5605338 | 0.79 | CA2 (0.54) | CA2KDM4EMMP2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233501-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS INC (US) | 2022-07-28 | — | — | US | claimed |
| CN-113943351-B | Fluorescent-labeled pasireotide derivative and application thereof | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113943351-A | Fluorescent-labeled pasireotide derivative and application thereof | 浙江湃肽生物有限公司南京分公司 | 2022-01-18 | — | — | CN | claimed |
| WO-2020167748-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| US-20200253926-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS, INC. | 2020-08-13 | — | — | US | claimed |
| JP-4733268-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| EP-1117409-B1 | BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | AVENTIS PHARMA GMBH (DE) | 2005-01-26 | — | — | EP | claimed |
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | claimed |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | GERLACH UWE (DE) | 2003-05-01 | — | — | US | claimed |
| US-6506937-B2 | Used as antiarrhythmics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| US-5607976-A | ANNTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | claimed |
| EP-0612724-B1 | Substituted benzenesulfonylureas and -thioureas, process for their preparation and their use as pharmaceuticals | HOECHST AG (DE) | 1996-12-27 | — | — | EP | claimed |
| CN-1137519-A | Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for production of pharmaceutical preparations, and pharmaceutical preparations containing them | HOECHST AG (DE) | 1996-12-11 | — | — | CN | claimed |
| CN-1134932-A | Substituted benzene sulfonyl urea and benzene sulfonyl thiourea and mfg. method and use as raw material for medicine | HOECHST AG (DE) | 1996-11-06 | — | — | CN | claimed |
| CN-1134415-A | Substituted benzene sulfone urea, benzenesulfonyl thiourea, its preparing method application of preparation for producing medicine and drugs containing them | HOECHST AG (DE) | 1996-10-30 | — | — | CN | claimed |
| CN-1134414-A | Substituted benzene sulfone urea, benzenesulfonyl thiourea its preparation, its application as medicine or diagnostic medicine and drugs containing it | HOECHST AG (DE) | 1996-10-30 | — | — | CN | claimed |
| CN-1109872-A | Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations b ased on these compounds | HOECHST AG (DE) | 1995-10-11 | — | — | CN | claimed |
| EP-0073507-B1 | SULFONYL UREAS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-16 | — | — | EP | claimed |
| EP-0031058-B1 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-04-04 | — | — | EP | claimed |
| EP-0006587-B1 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | UTS2R, EIF2S1, TST | CA2 780/4885KDM4E 2353/4885MMP2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.